Is Zoetis Inc. a good investment?
Zoetis Inc. (ZTS) is currently trading at 89.20 USD.
Market analysts have a consensus price target of 88.38 USD.
This suggests the asset is currently trading above analyst expectations.
In terms of valuation, the stock trades at a P/E ratio of 12.96.
This relatively low multiple may signal that Zoetis Inc. is undervalued compared to historical market norms.
Earnings Schedule:
Zoetis Inc. is expected to release its next earnings report on Nov. 5, 2026.
The market consensus estimate for Forward EPS is 6.44.
For income investors, Zoetis Inc. pays a dividend yield of 2.38%.
With a payout ratio of 34%, the dividend appears
sustainable.
Company Profile
Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health solutions for the animal health industry in the United States and internationally. The company commercializes products primarily across companion animals comprising dogs, cats, and horses; and species, including livestock, such as cattle, swine, poultry, fish, and sheep. It also offers parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other pharmaceutical, and animal health diagnostics. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health. It markets its products to veterinarians, livestock producers, and pet owners. The company has collaborated with Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health. Zoetis Inc. was incorporated in 2012 and is headquartered in Parsippany, New Jersey.
Community Discussion